На главную
Видео добавленное пользователем “Specialty Pharmacy Times”
Inventor of Sofosbuvir Discusses Limited Patient Access to Drug
 
03:16
Michael Sofia, PhD, the inventor of the groundbreaking hepatitis C drug sofosbuvir, discusses the difficulties patients have had in accessing the revolutionary treatment.
Просмотров: 3062 Specialty Pharmacy Times
Value of Specialty Pharmacy in Oncology
 
07:09
Ray Tancredi, RPh, MBA, CSP, vice president of specialty pharmacy development at Walgreens; Cheryl Allen, BS Pharm, MBA, vice president of business development and industry relations for Diplomat Pharmacy; Nicholas Karalis, RPh, of Elwyn Pharmacy Group; Stacey Ness, PharmD, RPh, CSP, MSCS, AAHIVP, director of specialty clinical services for Managed Healthcare Associates*; and Renee Rayburg, RPh, senior director of clinical consulting at Artemetrx, discuss the value that specialty pharmacies can bring to the field of oncology. Of all of the drugs that have been approved in the past 2 years, 22 of them have been for oncology. In the past, many oncology medications were infused in the provider’s office, but now that so many novel oncology drugs are oral, the touch point has shifted from the provider to the specialty pharmacy, according to Allen. The panelists agreed that specialty pharmacies can provide value in the oncology space by utilizing proactive side effect mitigation strategies, such as side effect management kits and tip cards that patients and providers can refer to. Specialty pharmacies can function as a liaison to coordinate communication between the patient and the provider, Ness said. As more of these new oncology drugs are approved, Allen noted, the benefit investigation conducted by the specialty pharmacy will have a great impact on the patient experience. Rayberg said that providers and patients are excited by the new drugs and new mechanisms of action, but payors have the burden of understanding all of the new options and combinations while keeping use on label when possible. *The views expressed are those of the individual alone and not of Managed Health Care Associates, Inc.
Просмотров: 1240 Specialty Pharmacy Times
Hepatitis C Patient Journey: Coping With Drug Side Effects
 
02:58
In part four, Jim Wilson, RPh, MBA, president of WilsonRx, discusses the difficulties he faced during treatment from interferon therapy following his liver transplant. Wilson was infected with an acute case of Non-A/Non-B hepatitis in 1975 due to a tainted blood supply but was not diagnosed with the disease until 1999. After receiving a liver transplant in 2006, he was finally cured of HCV in 2012 after enrolling in a 12-week clinical trial of the drug Harvoni.
Просмотров: 1213 Specialty Pharmacy Times
Treating RA with Methotrexate
 
05:55
Stanley B. Cohen, MD, details the roles of both oral and subcutaneous methotrexate in the treatment of rheumatoid arthritis.
Просмотров: 360 Specialty Pharmacy Times
Is There Value to Specialty Pharmacy Accreditation?
 
03:52
Ray Tancredi, RPh, MBA, CSP, vice president of specialty pharmacy development at Walgreens; Cheryl Allen, BS Pharm, MBA, vice president of business development and industry relations for Diplomat Pharmacy; Nicholas Karalis, RPh, of Elwyn Pharmacy Group; Stacey Ness, PharmD, RPh, CSP, MSCS, AAHIVP, director of specialty clinical services for Managed Healthcare Associates*; and Renee Rayburg, RPh, senior director of clinical consulting at Artemetrx, discuss the ramifications of accreditation for a specialty pharmacy. Even though accreditation is not mandatory, Allen pointed out that it may be tacitly required in a way, since payor networks and pharmaceutical manufacturers use accreditation to make decisions about specialty pharmacies. Accrediting bodies such as the Utilization Review Accreditation Committee (URAC) review all aspects of an organization’s policies and procedures, from human resources to disaster planning. The panelists agreed that accreditation can benefit specialty pharmacies by instituting consistent monitoring of quality parameters. *The views expressed are those of the individual alone and not of Managed Health Care Associates, Inc.
Просмотров: 573 Specialty Pharmacy Times
Overcoming Specialty Drug Cost Challenges
 
01:31
David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, Inc, discusses methods to address the growing cost of specialty medications. This video was recorded courtesy of Armada Health Care at the 2015 Armada Specialty Pharmacy Summit in Las Vegas, Nevada.
Просмотров: 572 Specialty Pharmacy Times
Management of High Cost Medications
 
06:00
Ray Tancredi, RPh, MBA, CSP, vice president of specialty pharmacy development at Walgreens; Cheryl Allen, BS Pharm, MBA, vice president of business development and industry relations for Diplomat Pharmacy; Nicholas Karalis, RPh, of Elwyn Pharmacy Group; Stacey Ness, PharmD, RPh, CSP, MSCS, AAHIVP, director of specialty clinical services for Managed Healthcare Associates*; and Renee Rayburg, RPh, senior director of clinical consulting at Artemetrx, discuss how to manage the high costs of specialty medications currently flooding the market. Prior authorization is a utilization management tool payors can use to control spending, Rayberg said, as well as ensuring a proper diagnosis and preventing off-label use of medication. Allen explained in detail how split-fill programs can benefit payors, not only by preventing the waste of high-cost medications, but also because it means there will be more frequent live touch points to follow up with the patient. Adequately educating the patient about how a split-fill program works can also be beneficial, Ness added. This split-fill strategy can also help keep medication costs at long-term care facilities down, Karalis said. In addition, nonbiased programs that do not base formulary decisions on reimbursement challenges and instead focus just on the appropriate patient care will ultimately produce the best outcomes, he concluded. *The views expressed are those of the individual alone and not of Managed Health Care Associates, Inc.
Просмотров: 314 Specialty Pharmacy Times
Episode 6: Evaluating Specialty Pharmacy: Reliable Methods to Measure Quality
 
07:04
Ray Tancredi, RPh, MBA, CSP, vice president of specialty pharmacy development at Walgreens; Cheryl Allen, BS Pharm, MBA, vice president of business development and industry relations for Diplomat Pharmacy; Nicholas Karalis, RPh, of Elwyn Pharmacy Group; Stacey Ness, PharmD, RPh, CSP, MSCS, AAHIVP, director of specialty clinical services for Managed Healthcare Associates*; and Renee Rayburg, RPh, senior director of clinical consulting at Artemetrx, discuss the various ways that quality of services can be measured within specialty pharmacies. The quality of the services provided by a specialty pharmacy can add value to the pharmaceutical manufacturer, because the representation of the pharmacy to its patients and providers can either reinforce the manufacturer’s brand or have a negative impact on the business, according to Tancredi. There are numerous methods of measuring quality. The panel described outcome measures such as time to therapy, time to fill prescriptions, duration that the patient is on therapy, converting scripts to filled prescriptions, persistency on therapy, access to payor networks, patient outreach capabilities, and the specialty pharmacy’s core offerings. For future improvements, accurate and thorough documentation will be key to determining quality outcomes at the patient level, Karalis said. When data is aggregated, individual rationales for actions, such as titrating up or down or interrupting a dose, may get lost. As a result, Allen noted the importance of designing a data set that provides actionable data to show what is happening in that specific patient’s journey. *The views expressed are those of the individual alone and not of Managed Health Care Associates, Inc.
Просмотров: 668 Specialty Pharmacy Times
The Future of Atopic Dermatitis
 
04:58
Panelists Peter L. Salgo, MD; Cheryl Allen, BS Pharm, MBA; Jeffrey D. Dunn, Pharm D, MBA; Ed Pezalla, MD, MPH; and Jonathan Silverberg, MD, PhD, MPH, outline the future of atopic dermatitis and provide final thoughts on the management of the disease.
Просмотров: 241 Specialty Pharmacy Times
It's Not 'Just A Uterine Fibroid'
 
02:14
Beth Wallace shares her journey leading up to her diagnosis with leiomyosarcoma.
Просмотров: 269 Specialty Pharmacy Times
Atopic Dermatitis: Dupilumab and Increase in Patient Quality of Life
 
01:54
Patient, Elizabeth Acuna, describes some of the medications she has been on, and currently is taking, to treat her atopic dermatitis, and their effect on her quality of life.
Просмотров: 392 Specialty Pharmacy Times
Challenges Ahead for Independent Specialty Pharmacies
 
01:19
Cheryl Allen, vice president of Industry Relations at Diplomat, discusses the largest challenges currently facing independent specialty pharmacies.
Просмотров: 305 Specialty Pharmacy Times
Rheumatoid Arthritis (RA): More Than a Disease of the Joints
 
35:20
Kevin Mange, MD, MSCE, head of North America Medical Immunology at Sanofi, provides a comprehensive overview of the considerations in the treatment of rheumatoid arthritis, which carries comorbidities that affect multiple organ systems.
Просмотров: 798 Specialty Pharmacy Times
Optimizing the Specialty Drug Pathway from Manufacturers to Pharmacies
 
03:12
Cheryl Allen, RPh, BSPharm, MBA, discusses how relationships can be improved between manufacturers, pharmacy benefit managers, and pharmacies.
Просмотров: 246 Specialty Pharmacy Times
How Specialty Pharmacies Can Gain Access to Limited Distribution Drugs
 
02:59
Cheryl Allen, vice president of Industry Relations at Diplomat, discusses how specialty pharmacies can best position themselves to access limited distribution drugs.
Просмотров: 284 Specialty Pharmacy Times
Sovaldi Inventor Sounds Off on High Drug Cost Controversy
 
01:42
Michael Sofia, PhD, the inventor of the groundbreaking hepatitis C drug sofosbuvir (Sovaldi), discusses the issues of high drug pricing and the cost of innovation.
Просмотров: 731 Specialty Pharmacy Times
How Do Biosimilars Differ from Generics?
 
01:27
Ron Lanton III, Esq., President, True North Political Solutions, discusses the significant differences between biosimilars and generic drugs.
Просмотров: 86 Specialty Pharmacy Times
Data Aggregation in Specialty Pharmacy
 
04:34
Ray Tancredi, RPh, MBA, CSP, vice president of specialty pharmacy development at Walgreens; Cheryl Allen, BS Pharm, MBA, vice president of business development and industry relations for Diplomat Pharmacy; Nicholas Karalis, RPh, of Elwyn Pharmacy Group; Stacey Ness, PharmD, RPh, CSP, MSCS, AAHIVP, director of specialty clinical services for Managed Healthcare Associates*; and Renee Rayburg, RPh, senior director of clinical consulting at Artemetrx, discuss the various types of data collected by specialty pharmacies and of interest to payors. According to Allen, manufacturers and payors are looking for more longitudinal data from specialty pharmacies, including the patient’s history of previous therapies and concomitant therapies to layer more information together beyond the diagnosis. Ness mentioned the growing importance of third-party information technology solutions that can help organizations capture comprehensive data in a usable manner. In the limited distribution environment, Tancredi said that there is a call for data analytics such as utilization reports, patient status reports, and inventory reports. The data collected by specialty pharmacies may never become public, but as noted by Karalis, they will see more requests by payors, patients, and providers for data such as side effects and discontinuation rates. *The views expressed are those of the individual alone and not of Managed Health Care Associates, Inc.
Просмотров: 476 Specialty Pharmacy Times
What Makes URAC Accreditation Standards Unique?
 
01:48
Heather Bonome, PharmD, director of Pharmacy Segment at URAC, discusses URAC specialty practice standards.
Просмотров: 425 Specialty Pharmacy Times
Sofosbuvir Inventor Discusses Impact of Discovering HCV Cure
 
01:32
Michael Sofia, PhD, the inventor of the groundbreaking hepatitis C drug sofosbuvir (Sovaldi), discusses the personal impact from curing hundreds of thousands of hepatitis C patients.
Просмотров: 449 Specialty Pharmacy Times
Access Considerations for PCSK9 Inhibitors
 
10:49
Cheryl Allen, BS Pharm, MBA; Bryan Bray, PharmD, CPP; Jeffrey Dunn, PharmD, MBA; Jennifer Reiter, PharmD, BCPS, BCACP, BCADM; and Peter L. Salgo, MD, share their perspectives on access considerations for proprotein convertase subtilisin/kexin type 9 inhibitors.
Просмотров: 83 Specialty Pharmacy Times
Role of Biosimilars in the Specialty Marketplace
 
05:44
Ray Tancredi, RPh, MBA, CSP, vice president of specialty pharmacy development at Walgreens; Cheryl Allen, BS Pharm, MBA, vice president of business development and industry relations for Diplomat Pharmacy; Nicholas Karalis, RPh, of Elwyn Pharmacy Group; Stacey Ness, PharmD, RPh, CSP, MSCS, AAHIVP, director of specialty clinical services for Managed Healthcare Associates*; and Renee Rayburg, RPh, senior director of clinical consulting at Artemetrx, discuss how biosimilars might be handled. The panelists agreed that the decisions made by payors and by each individual state will affect how specialty pharmacies handle biosimilars. Rayburg said that payors may not be able to rely on biosimilars to provide all of their savings, because unlike generic versions of small molecules, the manufacturers of the original biologics will continue to market their brands, and they may be able to be competitive through rebates and services. There are many questions that remain to be answered concerning biosimilars, the biggest one being whether they will be interchangeable. Another, raised by Allen, is whether manufacturers of the biosimilar products will offer the same types of services offered by manufacturers of the branded products. Regardless of the answers, the panelists agreed that specialty pharmacies will need to play a big role in education regarding biosimilars. *The views expressed are those of the individual alone and not of Managed Health Care Associates, Inc.
Просмотров: 194 Specialty Pharmacy Times
Are High Cost Hepatitis C Medications Worth the Price Tag?
 
09:47
Ray Tancredi, RPh, MBA, CSP, vice president of specialty pharmacy development at Walgreens; Cheryl Allen, BS Pharm, MBA, vice president of business development and industry relations for Diplomat Pharmacy; Nicholas Karalis, RPh, of Elwyn Pharmacy Group; Stacey Ness, PharmD, RPh, CSP, MSCS, AAHIVP, director of specialty clinical services for Managed Healthcare Associates*; and Renee Rayburg, RPh, senior director of clinical consulting at Artemetrx, discuss the unique cost-effectiveness conundrum caused by new hepatitis C medications. The recent breakthroughs in hepatitis C treatment come with cure rates of 90% and up with a hefty price tag: $1,000 a day or $84,000 for an average 12-week treatment duration. Ness pointed out that high cost drugs are usually for orphan disease states with very few patients, but the CDC estimates that approximately 3.2 million Americans have hepatitis C, creating a unique cost-effectiveness case study for the disease. To complicate matters further, Tancredi said that hepatitis C progresses slowly, and while 60% to 70% of patients will eventually have liver damage, only 5% to 20% of patients will progress to cirrhosis. Because of the cost and nature of the disease, appropriate use is very important with these higher cost agents, Karalis said. Manufacturers are helping to offset high copays for patients who participate in commercial medical insurance plans, Allen added, but patients within government payor systems face financial barriers to coverage, and specialty pharmacies are helping by leveraging funding organizations. There are now even newer combination therapies available that raise additional questions. The once-daily oral combination agent on the market ranges from 8 weeks to 24 weeks in treatment duration, which may lead to cost savings for some patients, but not for all of them, according to Rayburg. On the other hand, patients who require the longer duration for this drug, as well as for another new combination regimen, may incur costs that make $84,000 look like a deal. *The views expressed are those of the individual alone and not of Managed Health Care Associates, Inc.
Просмотров: 1242 Specialty Pharmacy Times
Leiomyosarcoma Patient Discusses Treatment Roadmap, Challenges
 
03:43
Beth Wallace discusses various treatments for leiomyosarcoma, including doxorubicin (Adriamycin), nicknamed the red devil.
Просмотров: 257 Specialty Pharmacy Times
RA Treatment Guidelines
 
03:51
Stanley B. Cohen, MD, outlines the current treatment guidelines for rheumatoid arthritis and how they are followed in clinical practice.
Просмотров: 159 Specialty Pharmacy Times
How SmartPill Bottles Can Improve Medication Adherence
 
01:15
Josh Stein, CEO and Co-founder of AdhereTech, discusses how smart pill technology can improve adherence in patients on a specialty drug regimen.
Просмотров: 887 Specialty Pharmacy Times
When Should Patients Switch from Statins to PCSK9 Inhibitors?
 
01:28
Mark Tesell, PharmD, BCPS, clinical consultant pharmacist at UMass Medical School, discusses the treatment switch from statins to PCSK9 inhibitors in patients with high cholesterol.
Просмотров: 120 Specialty Pharmacy Times
What Are the Benefits, Challenges of Operating a Specialty Pharmacy Linked to a Retail Giant?
 
01:38
Rina Shah, PharmD, Vice President, Pharmacy Operations and Specialty Pharmacy, Walgreens, discusses how operating a specialty pharmacy associated with a retail pharmacy can be beneficial.
Просмотров: 191 Specialty Pharmacy Times
Hepatitis C Patient Journey: The Impact on Quality of Life
 
02:47
In part six, Jim Wilson, RPh, MBA, president of WilsonRx, discusses how hepatitis C impacts the entire body.
Просмотров: 82 Specialty Pharmacy Times
Oral Versus IV Oncolytics
 
04:28
Peter L. Salgo, MD; Carl T. Henningson, MD; Noa Biran, MD; Steven L. D’Amato, RPh, BSPharm; and Arturo Loaiza-Bonilla, MD, MSEd, FACP, review the differences between oral and intravenous therapy for treating cancer, including patient considerations.
Просмотров: 117 Specialty Pharmacy Times
What Impact Does DIR Fees Have on Specialty Pharmacies?
 
02:01
Rinku Patel, PharmD, RPh, CEO and founder of KloudScript, discusses the impact of direct and indirect remuneration (DIR) fees.
Просмотров: 119 Specialty Pharmacy Times
What Lessons Have Been Learned from High Cost Hepatitis C Drugs?
 
01:26
Marc O'Connor, Chief Operating Officer of Curant Health, discusses the main takeaways from the impact of hepatitis C drugs on specialty pharmacy. This video was recorded courtesy of Armada Health Care at the 2015 Armada Specialty Pharmacy Summit in Las Vegas, Nevada.
Просмотров: 159 Specialty Pharmacy Times
TEAR Trial for Early Aggressive Rheumatoid Arthritis
 
04:13
Stanley B. Cohen, MD, reviews the methodology, results, and clinical importance of the TEAR trial for rheumatoid arthritis.
Просмотров: 77 Specialty Pharmacy Times
The Challenge of Getting Specialty Drugs from Manufacturer to Patient
 
01:32
Michael R. Hess, attorney with Bass Berry & Sims and outside general counsel to many of the largest independent specialty pharmacy companies, discusses how to overcome the hurdles that hinder patient access to specialty medications.
Просмотров: 96 Specialty Pharmacy Times
How Can Independent Specialty Pharmacies Best Manage DIR Fees?
 
01:30
Cheryl Allen, vice president of Industry Relations at Diplomat, discusses the impact of direct and indirect remuneration fees on specialty pharmacy.
Просмотров: 96 Specialty Pharmacy Times
New Products and Limited Distribution Channels
 
08:31
Ray Tancredi, RPh, MBA, CSP, vice president of specialty pharmacy development at Walgreens; Cheryl Allen, BS Pharm, MBA, vice president of business development and industry relations for Diplomat Pharmacy; Nicholas Karalis, RPh, of Elwyn Pharmacy Group; Stacey Ness, PharmD, RPh, CSP, MSCS, AAHIVP, director of specialty clinical services for Managed Healthcare Associates*; and Renee Rayburg, RPh, senior director of clinical consulting at Artemetrx, discuss the need for limited distribution, and developing trends moving forward. The panelists agreed that there is a place for limited distribution, such as for rare or orphan diseases, for products with complicated risk evaluation and mitigation strategy programs, or when detailed inventory reports are needed due to the costs of manufacturing. Karalis predicts that patient care could become increasingly complicated, especially in the oncology setting, where there is the potential for a single patient to be prescribed more than one medicine that is in limited distribution, which may mean having to deal with multiple specialty pharmacies at a time. Allen noted that specialty pharmacies, as providers of these limited distribution products, may be able to facilitate the integration of the different players involved in the patient’s treatment network. Ness, however, pointed out that not all specialty pharmacies excel at this task. Tancredi added that there will continue to be limited distribution until new products for orphan diseases or cancer can be handled uniformly throughout the continuum of pharmacies. *The views expressed are those of the individual alone and not of Managed Health Care Associates, Inc.
Просмотров: 228 Specialty Pharmacy Times
What Steps Need to be Taken to Combat DIR Fees?
 
01:28
Ron Lanton III, Esq, president, True North Political Solutions, LLC, takes a legal perspective on direct and indirect remuneration fees and how they affect specialty pharmacies.
Просмотров: 68 Specialty Pharmacy Times
How Can Specialty Pharmacy Benefit from Copay Assistance Programs?
 
01:56
Michael R. Hess, attorney with Bass Berry & Sims and outside general counsel to many of the largest independent specialty pharmacy companies, discusses copay and reimbursement assistance programs.
Просмотров: 95 Specialty Pharmacy Times
Identifying Appropriate Patients for PCSK9 Inhibitors
 
07:28
Cheryl Allen, BS Pharm, MBA; Bryan Bray, PharmD, CPP; Jeffrey Dunn, PharmD, MBA; Jennifer Reiter, PharmD, BCPS, BCACP, BCADM; and Peter L. Salgo, MD, discuss the challenges in identifying appropriate hypercholesterolemia patients to treat with proprotein convertase subtilisin/kexin type 9 inhibitors.
Просмотров: 63 Specialty Pharmacy Times
Specialty Pharmacy, Payer Goals in Atopic Dermatitis Management
 
09:09
Peter L. Salgo, MD; Ed Pezalla, MD, MPH; Cheryl Allen, BS Pharm, MBA; Jeffrey D. Dunn, Pharm D, MBA; and Jonathan Silverberg, MD, PhD, MPH, provide insight on specialty pharmacy and payer goals in the management of atopic dermatitis.
Просмотров: 58 Specialty Pharmacy Times
The Importance of Specialty Drug Therapy Management
 
01:08
Mark Tessell, PharmD, BCPS, clinical consultant pharmacist at UMass Medical School Clinical Pharmacy Services, discusses the components of successful medication therapy management.
Просмотров: 112 Specialty Pharmacy Times
How High Cost Oncology Drugs Are Changing Specialty Pharmacy
 
01:12
Jonathan Van Lare, PharmD, director of Clinical Services at Pharmacy Advantage, discusses the impact of oncology medications and how specialty pharmacies can adjust.
Просмотров: 89 Specialty Pharmacy Times
Biologics for RA
 
02:56
Cheryl Allen, BS Pharm, MBA, describes the use of biologics for the treatment of rheumatoid arthritis.
Просмотров: 66 Specialty Pharmacy Times
What is the Future of Biosimilars?
 
01:27
CEO of Avella Specialty Pharmacy Rebecca M. Shanahan, Esq., discusses how specialty pharmacies can best manage the rising cost of specialty drugs to improve outcomes for patients.
Просмотров: 73 Specialty Pharmacy Times
Specific Oral Oncolytics
 
07:00
Peter L. Salgo, MD; Noa Biran, MD; Carl T. Henningson, MD; Arturo Loaiza-Bonilla, MD, MSEd, FACP; and Steven L. D'Amato, RPh, BSPharm, outline specific oral oncolytics, including ixazomib for multiple myeloma and regorafenib for gastrointestinal malignancies.
Просмотров: 36 Specialty Pharmacy Times
Staying on Top of Specialty Pharmacy Trends
 
00:59
Rinku Patel, PharmD, RPh, founder and CEO of KloudScript, discusses the latest trends in the specialty pharmacy landscape.
Просмотров: 79 Specialty Pharmacy Times
Oral and Subcutaneous Methotrexate Use for RA
 
09:09
Cheryl Allen, BS Pharm, MBA, discusses the use of methotrexate for the treatment of rheumatoid arthritis and the advantages of use of subcutaneous methotrexate.
Просмотров: 189 Specialty Pharmacy Times
What are the Most Promising Specialty Drugs Currently in the Pipeline?
 
00:48
Sheena Babin, PharmD, business development and clinical pharmacy manager at Ochsner Health System, discusses promising specialty drugs to watch out for in the pipeline.
Просмотров: 42 Specialty Pharmacy Times
Improving Drug Utilization Management
 
01:11
Raulo Frear, PharmD, general manager of OmedaRx, discusses methods to enhance management of drug utilization programs.
Просмотров: 183 Specialty Pharmacy Times